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OBJECTIVES We sought to investigate the success rate and the acute and 12-month clinical outcome of
percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in the contem-
porary era.
BACKGROUND The technique of PCI involving CTO has improved over time. However, limited data on
acute and follow-up results in patients treated with PCI on CTO in recent years are available.
METHODS Four hundred nineteen consecutive patients scheduled for PCI of CTO of 30 days of
duration were enrolled in 29 centers; 390 CTOs were confirmed in 376 patients in an
independent core laboratory. The end points were technical and procedural success,
in-hospital and 12-month major adverse cardiac events (MACE) occurrence, and 12-month
symptomatic status.
RESULTS Technical and procedural success was obtained in 77.2% and 73.3% of lesions, respectively.
In-hospital major adverse cardiac events occurred in 5.1% of patients. Multivariate analysis
identified CTO length 15 mm or not measurable, moderate to severe calcifications,
duration 180 days, and multivessel disease as significant predictors of PCI failure. At 12
months, patients with a successful procedure experienced a lower incidence of cardiac deaths
or myocardial infarction (1.05% vs. 7.23%, p  0.005), a reduced need for coronary artery
bypass surgery (2.45% vs. 15.7%, p  0.0001), and were more frequently free of angina
(88.7% vs. 75.0%, p  0.008) compared with patients who had an unsuccessful procedure.
CONCLUSIONS Successful PCI was achieved in a high percentage of CTOs with a low incidence of
complications. At one-year follow-up, patients with successful PCI of a CTO had a
significantly better clinical outcome than those whose PCI was unsuccessful. (J Am Coll
Cardiol 2003;41:1672–8) © 2003 by the American College of Cardiology Foundation
Percutaneous coronary intervention (PCI) of chronic total
occlusion (CTO) is one of the major challenges in inter-
ventional cardiology. The primary success rate is relatively
low, mainly due to inability to cross the occlusion with the
guidewire (1–13), while the recurrence rate is higher than
that of subtotal stenoses (14,15). Moreover, the overall
procedure and fluoroscopy times are longer and equipment
use higher than with PCI of nonoccluded vessels (16).
Several reports, usually based on single-center experience,
have shown that the immediate success has improved over
time, along with the increased experience and skill of the
operators (3,7,12,13) and the availability of new specialized
guidewires or more sophisticated technologies for crossing
occluded arteries (17–22). In addition, randomized studies
have demonstrated that stent implantation reduces resteno-
sis and reocclusion rates (23–29). Furthermore, some retro-
spective studies suggest that successful PCI of a CTO
confers a long-term survival advantage (6,11–13), but this
issue has not been investigated with prospective studies.
Thus, we performed a prospective, multicenter, observa-
tional study—Total Occlusion Angioplasty STudy—
supported by GISE (Societa` Italiana di Cardiologia Inva-
siva), or TOAST-GISE, on consecutive patients treated
with PCI of a CTO in order to evaluate the success rate, the
in-hospital and clinical outcome, and their correlation with
predefined clinical and angiographic variables.
METHODS
Study design. From June 1999 to January 2000, a multi-
center, prospective, observational clinical study was con-
ducted in 29 Italian centers. All consecutive patients sched-
uled to undergo PCI on a CTO of a native coronary artery
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were considered for enrollment. The exclusion criteria were
the estimated duration of a CTO 30 days or an acute
myocardial infarction (MI) within the previous 30 days. No
other predefined clinical inclusion or exclusion criteria were
considered, and the indication for PCI was decided by
individual investigators at the participating centers. The
study protocol was approved by the institutional review
board at each participating center, and all patients provided
written informed consent.
The angiograms of the target procedures were sent to an
independent core angiographic laboratory at Milan Cardio-
vascular Research, that assessed all angiographic qualitative
and quantitative variables. The automated edge-detection
system CMS (Medis, Neunen, The Netherlands) was used
for quantitative coronary angiography.
The aim of the study was to investigate the procedural
success of PCI of CTO, in-hospital major adverse cardiac
events (MACE), one- and five-year MACE occurrence,
and anginal status in patients who underwent PCI of a
CTO. To evaluate the effect of the vessel patency on clinical
outcome avoiding the confounding effect of in-hospital
events such as Q-wave MI or coronary artery bypass surgery
(CABG), only patients discharged free of those events were
included in the follow-up analysis.
Definitions. A CTO was defined as obstruction of a native
coronary artery with no luminal continuity and with
Thrombolysis In Myocardial Infarction (TIMI) flow grade
0 or 1 (30). The duration of the occlusion had to be more
than 30 days, estimated from clinical events such as MI,
sudden onset or worsening of the symptoms, or proven by
previous angiography. If the duration of the occlusion was
uncertain, but the investigators had no clear reason to date
the CTO 30 days, the patient was enrolled.
Technical success was defined as restoration of TIMI
flow grade 2 or 3 with a residual stenosis of 50% assessed
by quantitative coronary angiography performed at the
angiographic core laboratory. Procedural success was de-
fined as technical success without in-hospital MACE.
Major adverse cardiac events were defined as death, Q-wave
and non–Q-wave MI, urgent CABG, or urgent repeat PCI.
The diagnosis of Q-wave MI was documented by the
presence of new pathologic Q waves on the electrocardio-
gram. Serum total creatine kinase was determined 8 and
24 h after the PCI, while creatine kinase-MB fraction was
measured only if total creatine kinase was above the upper
normal limit. Non–Q-wave MI was defined as any increase
of total creatine kinase with increase of MB fraction,
without new abnormal Q waves. At clinical follow-up,
MACE-free survival was defined as freedom from cardiac
death, Q-wave and non–Q-wave MI, or target lesion
revascularization (TLR), either surgical or percutaneous. All
deaths were considered cardiac unless otherwise docu-
mented. All MIs were counted as events, whether or not
associated with new revascularization procedure.
Interventional technique. The operators performed the
procedure according to their standard practices via the
femoral or brachial approach. All procedural and technical
details and the choice of devices were left to the operator’s
judgment. Ticlopidine (500 mg daily) or clopidogrel (75 mg
daily) was prescribed to all patients for four weeks after stent
implantations; aspirin was given indefinitely.
Follow-up. A follow-up visit or telephone interview was
scheduled at 30 days, 6 months, 1 year, and then yearly for
up to 5 years. An exercise tolerance test was recommended
after six months in event-free patients. In this report, the
data up to one year are presented.
Statistical analysis. Continuous data are presented as
mean  SD and differences are compared using Student t
test. Discrete variables are expressed as counts and percent-
ages. In two-by-two tables, differences were assessed by
Fisher exact test. In two-by-three and two-by-four tables,
differences were assessed by chi-square test. All statistical
tests were two-tailed.
Logistic regression analysis was used to assess the rela-
tionship between baseline clinical and angiographic charac-
teristics and technical success and to investigate the predic-
tive value of CTO success, together with baseline variables,
on MACE rate during follow-up. All analyses were per-
formed using SPSS version 11 statistical software (SPSS
Inc., Chicago, Illinois). A p value of 0.05 was considered
significant.
RESULTS
Between June 1999 and January 2000, 29 Italian centers
participated in the study for a median of 120 days (range 37
to 214 days). During the study period, a total of 6,322 PCIs
were performed in the participating centers. In 419 PCIs, a
total of 443 CTO were targeted. The enrollment per center
was 10 patients in 9 centers, 11 to 20 patients in 14
centers, and 20 patients in 6 centers. The prevalence of
patients with CTO on the overall PCI population in the
different centers was 7.1  2.9% (range 2.9% to 13.5%).
Subsequently, 19 CTOs were excluded because either the
angiogram of the procedure was not available or the image
quality did not allow an adequate analysis in the core
laboratory. Of the remaining 424 CTOs, 34 (8%) were
excluded because they were judged to be subtotal at core
laboratory evaluation. Interestingly, in 32 (94.1%) of those
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CTO  chronic total occlusion
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial
Infarction
TLR  target lesion revascularization
TOAST-GISE  Total Occlusion Angioplasty Study-
Societa` Italiana di Cardiologia
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cases, the PCI was successful. Thus, the final study popu-
lation consisted of 376 patients with 390 CTOs targeted.
Baseline clinical characteristics. The baseline clinical
characteristics of the patients are shown in Table 1. The
majority of patients had a history of a previous MI (61.7%
in the region of myocardium supplied by the target vessel)
and had symptoms of angina. About one-half of the patients
presented with multivessel disease. The viability of the
myocardium supplied by the target vessel was not investi-
gated by protocol, but in 70% of patients the presence of
normal or only reduced regional systolic wall motion of that
area evaluated either by angiography or echocardiography,
suggested the presence of viable myocardium.
Procedural outcome and in-hospital complications.
Technical success was obtained in 77.2% and procedural
success in 73.3% of the lesions (Table 2). Among the failed
procedures, inability to cross the lesion with a guidewire,
inability to cross with a balloon, and inability to dilate were
the reason for failure in 81%, 11.4%, and 7.6% of cases,
respectively. One patient died because of massive pulmonary
embolism 48 h after successful PCI. Two patients under-
went emergency CABG: one patient developed a retrograde
dissection of the left main trunk during an attempt to
recanalize the left anterior descending artery and the other
patient presented subacute thrombosis of a stent implanted
in a nonoccluded vessel after an unsuccessful procedure on
the CTO. This patient was treated with repeat PCI and
then CABG and eventually developed a Q-wave MI.
Another patient presented subacute stent thrombosis and
was treated with repeat PCI and developed a non–Q-wave
MI. In a further 15 patients, a postprocedural increase in both
total creatine kinase and MB fraction was found, with a total of
16 non–Q-wave MIs (4.3%). Perforation of the vessel occurred
in 8 patients (2.1%) without relevant clinical sequelae. Overall,
in-hospital MACE occurred in 19 patients (5.1%).
CTO characteristics. All baseline characteristics of the
target lesions and their relationship with technical success
are shown in Table 3. Most CTOs presented TIMI flow
grade 0. In 30% of the cases, the duration of the CTO could
not be estimated, whereas in the remaining cases the median
estimated duration was 70 days (interquartile range: 40,
120). In 50% of the cases, the length of the CTO could not
be assessed; in the remaining cases the mean CTO length was
13.4  9.13 mm (median 10.7 mm; range 1.5 to 63 mm).
Procedure-related characteristics. In 165 (43.9%) pa-
tients, the procedure was done at the end of diagnostic
angiogram. A large variety of guidewires with different
mechanical properties were used, and they were grouped
into three categories, based on the producers’ specifications:
soft or floppy in 35.1% of lesions, intermediate in 34.4%,
and stiff or dedicated to CTO treatment in 30.5%. At least
one stent was implanted in 89.7% of successfully recanalized
CTOs. Glycoprotein IIb/IIIa antagonists were used in 39
(10.4%) patients.
After successful procedure, the average proximal refer-
ence diameter was 3.13  1.66 mm; the minimal luminal
diameter was 2.27  0.56 mm, and diameter stenosis was
22.53 13.32% at quantitative coronary angiography. In 76
patients, PCI was performed on at least one additional
vessel.
Determinants of procedural success. In univariate analy-
sis, the characteristics that had a significant relationship
with technical outcome were the vessel site of CTO,
duration and length of CTO, stump morphology, and
presence of multivessel disease. No other characteristic was
found to be correlated with PCI outcome (Table 3). At
multivariate analysis, CTO length 15 mm or not measur-
able, duration 180 days, presence of moderate to severe
calcifications, presence of multivessel disease, and stump
morphology not clearly identifiable were associated with the
technical failure of the PCI (Table 4).
Table 2. Technical and Procedural Success and In-Hospital
Complications of 376 Patients
Technical success 301 (77.2%)*
Procedural success 286 (73.3%)*
Death 1 (0.26%)
Q-wave MI 1 (0.26%)
Non–Q-wave MI 16 (4.3%)
Urgent CABG 2 (0.53%)
Urgent repeat PCI 2 (0.53%)
Cerebrovascular accident 0
Vessel perforation 8 (2.1%)*
In-hospital MACE 19 (5.1%)
*Referring to 390 CTOs total.
MACE  major adverse cardiac event (death, MI, urgent repeat PCI, and urgent
CABG). Other abbreviations as in Table 1.
Table 1. Patient Baseline Characteristics for CTO Success and
Failure Groups
All Patients
(n  376)
CTO Success
(n  289)
CTO Failure
(n  87)
Age (yrs, mean  SD) 58.3  10.2 58.0  9.9 59.4  10.9
Male 323 (85.9%) 249 (86.2%) 74 (85.1%)
Family history of CAD 158 (42.0%) 126 (43.6%) 32 (36.8%)
Diabetes 67 (17.8%) 50 (17.3%) 17 (19.5%)
Insulin treatment 7 (1.86%) 4 (1.38%) 3 (3.45%)
Hypertension 200 (53.2%) 153 (52.9%) 47 (54.0%)
Hyperlipidemia 218 (58.0%) 169 (58.5%) 48 (56.3%)
Smoking
Active 134 (35.6%) 107 (37.0%) 27 (30.3%)
Previous 115 (30.6%) 83 (28.7%) 32 (36.8%)
Prior MI 258 (68.6%) 198 (68.5%) 60 (69.0%)
Prior CABG 19 (5.0%) 13 (4.5%) 6 (6.9%)
Prior PCI 48 (12.8%) 32 (11.1%) 16 (18.4%)
Angina
Stable 264 (70.2%) 203 (70.2%) 61 (70.1%)
Unstable 66 (17.5%) 52 (18.0%) 14 (4.8%)
Silent ischemia 41 (10.9%) 29 (10.0%) 12 (13.8%)
NYHA class 3 to 4 15 (4.0%) 9 (3.1%) 7 (8.0%)
Multivessel disease 181 (48.1%) 129 (44.6%) 52 (59.8%)*
Ejection fraction
(%, mean  SD)
55.9  9.7 55.7  9.6 56.3  10.1
*p  0.014.
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease;
CTO  chronic total occlusion of coronary artery; CTO success  technical success
on all CTOs targeted in a patient; LV  left ventricle; MI  myocardial infarction;
NYHA  New York Heart Association; PCI  percutaneous coronary intervention.
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One-year follow-up. The one-year clinical follow-up is
complete for 369 of 373 (98.9%) patients who were dis-
charged free of Q-wave MI or urgent CABG. During
follow-up, patients with a successful procedure experienced
a significantly lower incidence of overall MACE, cardiac
deaths, and composite end point cardiac death or MI, as
well as a reduced need for CABG (Table 5). Because the
only significant difference in baseline characteristic between
patients with CTO success and CTO failure was the
prevalence of multivessel disease (Table 1), we analyzed
separately patients with single-vessel and multivessel disease
(Table 5). The excess of cardiac death or MI was evident
only in patients with multivessel disease.
Two noncardiac deaths, occurring one and nine months
after enrollment, were caused, respectively, by esophageal
cancer and stroke. The other four fatalities were considered
cardiac deaths. Only one Q-wave MI was observed and was
not related to the study CTO. During follow-up, seven
patients with failed recanalization underwent a repeat PCI
involving the target vessel (four cases of a second attempt at
the CTO and three cases of transmyocardial laser revascu-
larization that was counted, for the purpose of this study, as
an equivalent of TLR).
In a multivariate analysis including all baseline character-
istics listed in Table 1, the only variable associated with
MACE-free survival was the initially successful PCI (odds
ratio 0.24, 95% confidence interval 0.07 to 0.80, p 0.018).
No independent predictor of freedom from death or MI
could be identified.
The clinical status and exercise tolerance at 12 months in
308 event-free patients are shown in Table 6. Patients with
a successful CTO procedure presented significantly less
anginal symptoms and could more frequently perform a
negative exercise test than patients with a failed procedure.
DISCUSSION
Study design. The study was designed to look at the state
of the art of PCI in CTO. The available data on this subject
are derived from studies that present substantial limitations.
Most studies reported early results from single centers,
which tend to be particularly experienced in this subset of
patients (1–11). In recent years, various guidewires and
other more complex devices designed for CTO treatment
have become available. Several studies described the results
of such new devices in selected patients (17–23), but there
are no data on their overall impact on the procedural
outcomes in unselected patients. Therefore, limited infor-
mation on the incidence and results of PCI of CTO in
contemporary interventional practice is available.
Another important methodologic limitation of previous
studies dealing with PCI of CTO is the absence of an
independent assessment of qualitative and quantitative an-
Table 3. Univariate Analysis of CTO Characteristics Relevant
to Technical Success
CTO Baseline
Characteristics
No. of
CTOs (%)
Technical
Success
n (%)
p
Value
Vessel 0.017
LMCA* 1 1 (100)
LAD 156 131 (84.0)
LCX 86 59 (68.6)
RCA 147 110 (74.8)
Duration (days) 0.001
30–89 150 126 (84.0)
90–179 72 62 (86.1)
180 51 32 (62.7)
Not determinable 117 81 (69.2)
Length (mm) 0.016
8 66 59 (89.4)
8–14.9 65 54 (83.1)
15 65 49 (75.4)
Not determinable 194 139 (71.6)
TIMI flow 0.074
Grade 0 322 242 (75.2)
Grade 1 65 56 (86.2)
Calcification 0.051
Absent to mild 305 239 (78.4)
Moderate to severe 23 13 (56.5)
Not determinable 62 49 (79.0)
Stump morphology 0.001
Abrupt 157 117 (74.5)
Tapered 167 142 (85.0)
Not determinable 66 42 (63.6)
Side branch from stump 0.457
Absent 235 178 (75.7)
Present 149 118 (79.2)
Bridging collaterals 0.349
Absent 270 213 (78.9)
Present 113 84 (74.3)
Vessel diameter (mm) 0.244
2.4 81 65 (80.2)
2.4–2.89 89 73 (80.0)
2.9 87 68 (78.2)
Not determinable 133 95 (71.4)
LV wall motion 1.000
Normal or hypokinetic 264 206 (78.0)
Akinetic or dyskinetic 97 76 (78.4)
Number of CTO PCI/center 0.140
20 211 173 (82.0)
20 179 128 (71.5)
In few cases, angiographic characteristics such as TIMI flow, side branch from stump,
bridging collaterals, and LV wall motion were not determinable. These cases are not
included in the Table. Number of CTO PCI/center indicates the number of CTOs
included in the registry by the participating centers. *The single case of LMCA CTO
was excluded from chi-square computation. Therefore, the p value refers only to the
differences among LAD, LCX, and RCA.
LAD  left anterior descending artery; LCX  left circumflex artery; LMCA 
left main coronary artery; LV  left ventricle; RCA  right coronary artery; TIMI
 Thrombolysis In Myocardial Infarction. Other abbreviations as in Table 1.
Table 4. Multivariable Predictors of Technically Unsuccessful
Procedures
Hazard
Ratio
95% Confidence
Limits
p
Value
Length 15 vs. 8 mm 3.9 1.1–13.5 0.028
Length not measurable
vs. 8 mm
3.8 1.2–10.8 0.019
Moderate to severe calcification 3.5 1.1–10.1 0.023
Duration 180 days 3.1 1.3–7.4 0.013
Multivessel disease 2.3 1.2–4.3 0.009
Stump morphology not
discernable
2.2 1.0–4.8 0.048
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giographic parameters. Obviously, the angiographic assess-
ment is critical in excluding subtotal lesions from the study
group and in validating important end points such as
procedural success. The possibility to predict which CTOs
are more likely to be treated successfully is still of utmost
importance for patient selection, but the criteria for such
selection are derived from studies that are conditioned by
the above-mentioned limitations.
In this study, the success of the PCI of CTO was defined
as residual stenosis 50%. In most recent studies the
threshold value for success is 30% residual stenosis. How-
ever, most of those studies regard selected patients with
subtotal stenosis undergoing stent implantation, whereas
our study included consecutive patients with CTO not
necessarily treated with stenting. In addition, we favored the
concept of “open vessel,” that is the restoration of antegrade
flow, that is not limited by a residual stenosis of 50%.
Furthermore, we planned a clinical follow-up of five years
because an increasing number of studies (6,11–13) suggest
the unfavorable long-term outcome of patients with unsuc-
cessful recanalization of CTO.
In-hospital results. Of the 424 lesions evaluated at the
core laboratory, 34 (8%) were excluded, being judged
subtotal stenoses. These cases were distributed among the
participating centers and included those with extensive
experience and high-volume activity. In these lesions, a
successful dilation was obtained in 32 out of 34 (94.1%)
lesions. In the absence of an independent angiographic
assessment of baseline CTO characteristics, these lesions
would have been included in the study and the success rate
would have spuriously increased. This finding, previously
not reported, underlines the importance of an accurate
angiographic analysis to avoid the inclusion of subtotal
stenoses in CTO series. The technical and procedural
success rates (77.2% and 73.3%, respectively) observed in
this study were relatively high and compare favorably with
previously published single-center data (1–13) that varied
between 51% and 73%. It cannot be argued from our data
whether this high success rate was due to increased operator
experience, better case selection, or availability of newer
equipment, particularly guidewires dedicated to CTO treat-
ment. Interestingly, the higher success rate was not associ-
ated with an increase in acute complication rate, potentially
related to the use of more aggressive devices and techniques.
Major adverse cardiac events occurred in 19 (5.1%) patientsTa
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Table 6. Clinical Status After 12 Months of a PCI on a CTO
in Patients Discharged Free of Q-Wave MI and CABG and
MACE-Free During Follow-Up
CTO Success
(n  248)
CTO Failure
(n  60) p Value
No angina 220 (88.7%) 45 (75.0%) 0.008
ETT performed 210 (84.7%) 42 (70.0%) 0.010
Maximal ETT 155 (62.5%) 20 (33.3%) 0.0001
Negative ETT 181 (73.0%) 28 (46.7%) 0.0001
ETT  exercise tolerance test. Other abbreviation as in Tables 1 and 2.
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with a prevalence of non–Q-wave MI (16 [4.25%] patients).
Clearly, the incidence of such events depends on the
definition criteria. It is likely that, using more stringent
criteria, based on creatine kinase-MB fraction or troponin
elevation, the observed rate of non–Q- wave MI would have
been higher. Uneventful vessel perforation occurred in eight
cases (2.1%). These complication rates are similar to those
reported in most other studies (1,3–5,8,12,13,17).
Predictors of success. At univariate analysis, the presence
of multivessel disease, vessel site of CTO, CTO duration,
CTO length, and stump morphology were significantly
associated with the procedural outcome (Table 3). At
multivariate analysis, the presence of multivessel disease,
CTO length 15 mm or not measurable, the presence of
moderate to severe calcifications of CTO, duration 180
days, and not-determinable stump morphology were con-
firmed to be associated with a procedural failure (Table 4).
Nonidentifiable angiographic characteristics, such as CTO
length and stump morphology, could be related, at least in
some cases, to inadequate procedural methodology, such as
poor image quality.
With regard to CTO duration, an increase in PCI failures
was observed only in CTOs lasting more than six months.
Also, the reduced CTO success in patients with multivessel
disease, already reported (6,12,13), may be related to a more
extensive and chronic disease, although the influence of
selection criteria cannot be ruled out.
Several angiographic variables identified as negative pre-
dictors of success in previous studies, such as the presence of
side branch at CTO stump (8,9), bridging collaterals (3,8),
abrupt stump morphology (3,6–9), and TIMI flow grade 0
(1,6) had no predictive value in our study.
Comparison of predictors of success between the different
studies is unreliable for the following reasons. Most studies
were relatively small (1,2,5, 9,11,12) and lacked the statis-
tical power to identify such factors. In the larger studies,
information about some important variables, such as CTO
duration and/or angiographic morphology, was incomplete
or absent (3,4,6,13). In addition, the definition of CTO
varied greatly, with studies including (1,3,6–8,13,14,19,20)
or excluding (2,5,10,17,21) TIMI flow grade 1 CTO, others
including occlusions as recent as three days old (3,4), and
others excluding CTO of less than three (12,19), two (10)
or one (21) month(s) of duration.
One-year follow-up. During the 12 months following
PCI of CTO, we found a significantly higher incidence of
cardiac death, combined rate of cardiac death and MI, and
CABG in patients with a failed procedure as compared with
patients with a successful PCI. At multivariate analysis, the
only factor associated with one-year MACE-free survival
was the successful procedure; no independent predictor of
death or MI was identified. This excess of cardiac death and
MI in patients with failed CTO PCI has been reported in
other studies (6,11–13), but it has never been observed as
early as at 12 months. This finding, although statistically
significant, is based on the occurrence of few events and
needs to be confirmed during a longer follow-up. In patients
with failed PCI, the higher need for CABG surgery is not
unexpected and it has already been reported in several
studies (4,6,11,12).
Analyzing patients with single-vessel and multivessel
disease separately, we found that a higher rate of combined
cardiac death and MI was evident only in patients with
multivessel disease (Table 5). In both single-vessel and
multivessel disease, the TLR rate after a successful proce-
dure was remarkably low (8.7% and 15%, respectively). This
finding can be related to the extensive use of stents and to
the fact that no routine angiographic control was scheduled.
On the other hand, in event-free patients after successful PCI,
88.7% of the patients had no angina symptoms and 73.8% of
those performing an exercise test were able to reach the
maximum heart rate for age, reflecting the good functional
outcome of the procedure (Table 6). A better clinical outcome
(angina status and exercise tolerance) after successful proce-
dures was reported in other studies in the stent era (21).
Study limitations. The results of the study may have been
influenced by selection criteria, operator experience, and tech-
nique varying among the participating centers. Therefore, they
may not be fully reproducible under different conditions. We
have no information about collateral flow to the CTO vessel
because in most of the angiograms analyzed, the baseline
diagnostic coronary angiography was not included. In our
study, the clinical relevance of successful PCI of a CTO is
based on the comparison with patients in whom the procedure
was unsuccessful. The question as to whether recanalization of
a CTO can lead to a better clinical outcome and in which
patients should be evaluated with randomized studies.
Conclusions. These data represent the largest reported
multicenter series of consecutive patients treated with PCI
of CTO with independent core laboratory evaluation of all
angiographic variables. A high success rate with a low inci-
dence of complications was observed. Predictors of a failed
procedure were multivessel disease and CTO characteristics
such as length, duration, and presence of moderate to severe
calcifications. Other angiographic characteristics, previously
reported as associated with procedural outcome, did not
confirm their predictive value. A successful PCI was associated
with better clinical outcome at one year, with lower need of
CABG, lower cumulative rate of cardiac death and MI, and
better clinical status with less angina and better exercise
tolerance. Percutaneous coronary intervention can be an effec-
tive therapeutic option in selected patients with CTO.
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APPENDIX
Sites and investigators participating in TOAST-
GISE. The number of patients enrolled in each center is
given in parenthesis. Genoa: P. Rubartelli, C. Giachero
(37); Mercogliano: P. Rubino, L. Salemme (35); Ancona:
R. Piva, G. Gabrielli (34); Milan: A. Colombo, C. Di
Mario (34); Udine: G. Bernardi, L. Spedicato (25); Milan:
F. Bedogni, M. Onofri (22); Legnano: S. De Servi, M.
D’Urbano (18); Treviso: Z. Olivari, M. Spolverato (17);
Pescara: L. Paloscia, G. Contegiacomo (13); Bologna: A.
Marzocchi, C. Marozzini (13); Pedara: S. Tolaro, R. Raciti
(13); Cagliari: A. Bande, B. Loi (13); Salerno: P. Giudice,
C. Baldi (12); Brescia: L. Niccoli, F. Ettori (12); Napoli: F.
Piscione, G. De Luca (12); Bari: A. Bortone, E. De Cillis
(11); Pisa: A. S. Petronio, U. Limbruno (10); Cuneo: G.
Steffenino, A. Della Valle (10); Rozzano: P. Presbitero, L.
Maiello (10); Rome: R. Violini, A. Parma (10); Modena: A.
Benassi, G. D’Annibale (9); Perugia: C. Giombolini, S.
Santucci (8); Catania: C. Tamburino, B. Francaviglia (8);
Rome: M. A. Mazzari, C. Trani (8); Novara: C. Cernigli-
aro, M. Sansa (7); Brescia: G. B. Danzi, C. Capuano (5);
Rome: P. Gioffre`, F. Tomai (5); Bari: A. Gaglione, F.
Tiecco (5); Palermo: G. Saccone, O. Manzi (3). Steering
Committee: Z. Olivari, P. Rubartelli, F. Piscione, F. Ettori,
A. Fontanelli. Core Angiographic Laboratory: MCR,
Milan, Italy, M. A. Bonardi. Data Coordinating Center:
Cardioricerche, Milan, Italy: G. Lanteri.
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